

References

This is the reference list to the ACE Clinical Guideline "Community-acquired pneumonia – assessment, diagnosis and antibiotic prescribing".

1. Nguyen AD, Rajasurya V. Typical bacterial pneumonia. [Updated 2026 Aug 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK534295/> (Accessed 16 May 2026)
2. Ministry of Health, Singapore. Principal causes of death. Available from: <https://www.moh.gov.sg/resources-statistics/singapore-health-facts/principal-causes-of-death> (Accessed 16 May 2026)
3. Ministry of Health, Singapore. Top 10 conditions of hospitalisation. Available from: <https://www.moh.gov.sg/others/resources-and-statistics/top-10-conditions-of-hospitalisation/> (Accessed 16 May 2026)
4. Liam CK, Pang YK, Poosparajah S, *et al.* Community-acquired pneumonia: an Asia Pacific perspective. *Respirology*. 2007;12(2):162-164.
5. Lee KH, Hui KP, Tan WC, *et al.* Severe community-acquired pneumonia in Singapore. *Singapore Med J*. 1996;37(4):374-377.
6. Aliberti S, Cook GS, Babu BL, *et al.* International prevalence and risk factors evaluation for drug-resistant *Streptococcus pneumoniae* pneumonia. *J Infect*. 2019;79(4):300-311.
7. Kim SH, Chung DR, Song JH, *et al.* Changes in serotype distribution and antimicrobial resistance of *Streptococcus pneumoniae* isolates from adult patients in Asia: Emergence of drug-resistant non-vaccine serotypes. *Vaccine*. 2020;38(38):6065-6073.
8. Vasoo S, Singh K, Hsu LY, *et al.* Increasing antibiotic resistance in *Streptococcus pneumoniae* colonizing children attending day-care centres in Singapore. *Respirology*. 2011;16(8):1241-1248.
9. Mamishi S, Moradkhani S, Mahmoudi S, *et al.* Penicillin-Resistant trend of *Streptococcus pneumoniae* in Asia: A systematic review. *Iran J Microbiol*. 2014;6(4):198-210.
10. Song JH, Chang HH, Suh JY, *et al.* Macrolide resistance and genotypic characterization of *Streptococcus pneumoniae* in Asian countries: a study of the Asian Network for Surveillance of Resistant Pathogens (ANSORP). *J Antimicrob Chemother*. 2004;53(3):457-463.
11. Wang H, Chen M, Xu Y, *et al.* Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010. *Int J Antimicrob Agents*. 2011;38(5):376-383.
12. Kalin G, Alp E, Chouaikh A, *et al.* Antimicrobial multidrug resistance: clinical implications for infection management in critically ill patients. *Microorganisms*. 2023;11(10):2575.

13. Cilloniz C, Videla A, Pericàs JM. Identifying predictors of treatment failure with community-acquired pneumonia: an update. *Expert Rev of Anti Infect Ther*. 2025;23(9):797-809.
14. Torres A, Cilloniz C, Niederman MS, *et al*. Pneumonia. *Nat Rev Dis Primers*. 2021;7(1):25.
15. Rider AC, Frazee BW. Community-acquired pneumonia. *Emerg Med Clin North Am*. 2018;36(4):665-683.
16. Lüthi-Corridori G, Roth AI, Boesing M, *et al*. Diagnosis and therapy of community-acquired pneumonia in the emergency department: a retrospective observational study and medical audit. *J Clin Med*. 2024;13(2).
17. Best Practice Advocacy Centre New Zealand (BPAC, New Zealand). The management of community-acquired pneumonia. 2024. Available from: <https://bpac.org.nz/2024/pneumonia.aspx> (Accessed 16 May 2026)
18. The National Institute for Health and Care Excellence (NICE). Pneumonia: diagnosis and management. NICE [NG250]. 2025. Available from: <https://www.nice.org.uk/guidance/ng250> (Accessed 16 May 2026)
19. Hill AT, Gold PM, El Solh AA, *et al*. Adult outpatients with acute cough due to suspected pneumonia or influenza: CHEST guideline and expert panel report. *CHEST*. 2019;155(1):155-167.
20. The National Institute for Health and Care Excellence (NICE). Pneumonia in adults: diagnosis and management. NICE [CG191]. 2023. <https://www.nice.org.uk/guidance/cg191> (Accessed 16 May 2026)
21. Dzahini O, Singh N, Taylor D, *et al*. Antipsychotic drug use and pneumonia: Systematic review and meta-analysis. *J Psychopharmacol*. 2018;32(11):1167-1181.
22. Strich JR, Heil EL, Masur H. Considerations for empiric antimicrobial therapy in sepsis and septic shock in an era of antimicrobial resistance. *J Infect Dis*. 2020;222(Suppl 2):S119-S131.
23. Metlay JP, Waterer GW, Long AC, *et al*. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med*. 2019;200(7):e45-e67.
24. InformedHealth.org [Internet]. Pneumonia: Learn More – What are the different types of pneumonia? Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2026. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK525768/> (Accessed 16 May 2026)
25. Philippine Society for Microbiology and Infectious Diseases (PSMID). Clinical Practice Guidelines: Management and Prevention of Adult Community Acquired Pneumonia. 2025. Available from: <https://psmid.org/cpg-management-and-prevention-of-adult-community-acquired-pneumonia/> (Accessed 16 May 2026)

26. Jones BE, Ramirez JA, Oren E, *et al.* Diagnosis and management of community-acquired pneumonia: an official American thoracic society clinical practice guideline. *Am J Respir Crit Care Med.* 2026;212(1):24-44.
27. Spiteri MA, Cook DG, Clarke SW. Reliability of eliciting physical signs in examination of the chest. *Lancet.* 1988;1(8590):873-875.
28. Moberg AB, Taléus U, Garvin P, *et al.* Community-acquired pneumonia in primary care: clinical assessment and the usability of chest radiography. *Scand J Prim Health Care.* 2016;34(1):21-27.
29. Pocheptnia S, Grabczak EM, Johnson E, *et al.* Imaging in pulmonary infections of immunocompetent adult patients. *Breathe (Sheff).* 2024;20(1):230186.
30. Chalmers JD, Singanayagam A, Akram AR, *et al.* Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. *Thorax.* 2010;65(10):878-883.
31. Edwin N, Attaree R. An approach to chest infections in adults. *The Singapore Fam Physician.* 2015;41(3):30-35.
32. Luna HI, Pankey G. The utility of blood culture in patients with community-acquired pneumonia. *Ochsner J.* 2001;3(2):85-93.
33. Jun KN, Yu QH, Lateef F. Is it always necessary to take blood cultures before starting antibiotics in the emergency department? a review of usefulness of blood cultures in community-acquired pneumonia, cellulitis, urinary tract infection and pyelonephritis. *Int J Crit Care Emerg Med.* 2019;5:062.
34. Zhang D, Yang D, Makam AN. Utility of blood cultures in pneumonia. *Am J Med.* 2019;132(10):1233-1238.
35. Miyashita N, Shimizu H, Ouchi K, *et al.* Assessment of the usefulness of sputum Gram stain and culture for diagnosis of community-acquired pneumonia requiring hospitalization. *Med Sci Monit.* 2008;14(4):CR171-176.
36. Taylor E, Marrie T, Fine M, *et al.* Observations from a multicentre study on the use of the sputum specimen in patients hospitalized with community-acquired pneumonia. *Can J Infect Dis.* 1999;10(1):39-46.
37. Falguera M, Ruiz-González A, Schoenenberger JA, *et al.* Prospective, randomised study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalised patients with community-acquired pneumonia. *Thorax.* 2010;65(2):101-106.
38. Bellew S, Grijalva CG, Williams DJ, *et al.* Pneumococcal and legionella urinary antigen tests in community-acquired pneumonia: prospective evaluation of indications for testing. *Clin Infect Dis.* 2019;68(12):2026-2033.

39. Gao Y, Zhao Y, Liu M, *et al.* Antiviral medications for treatment of nonsevere Influenza: a systematic review and network meta-analysis. *JAMA Intern Med.* 2025;185(3):293-301.
40. Stichting Wrekgroep Antibioticabeleid (SWAB). Management of Community-Acquired Pneumonia in Adults: the 2024 Practice Guideline from The Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT). SWAB. 2024. Available from <https://swab.nl/nl/exec/file/download/300> (Accessed 16 May 2026)
41. Rahme D, Chmairie HN, Salameh P. Appropriateness of empiric antibiotic therapy for community-acquired pneumonia: A multicenter cross-sectional study. *Explor Res Clin Soc Pharm.* 2025;20:100669.
42. Seo C, Corrado M, Lim R, *et al.* Guideline-concordant therapy for community-acquired pneumonia in the hospitalized population: a systematic review and meta-analysis. *Open Forum Infect Dis.* 2024;11(7):ofae336.
43. Regunath H, Oba Y. Community-Acquired Pneumonia. Treasure Island (FL): StatPearls Publishing; 2024. [Updated 26 Jan 2026]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK430749/> (Accessed 16 May 2026)
44. Chiang WC, Teoh OH, Chong CY, *et al.* Epidemiology, clinical characteristics and antimicrobial resistance patterns of community-acquired pneumonia in 1702 hospitalized children in Singapore. *Respirology.* 2007;12(2):254-261.
45. Eliakim-Raz N, Robenshtok E, Shefet D, *et al.* Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. *Cochrane Database Syst Rev.* 2012;2012(9):Cd004418.
46. Viasus D, Núñez-Ramos JA, Vilorio SA, *et al.* Pharmacotherapy for community-acquired pneumonia in the elderly. *Expert Opin Pharmacother.* 2017;18(10):957-964.
47. Ocropsoma S, Anzueto A, Restrepo MI. Advancements and challenges in the management of pneumonia in elderly patients with COPD. *Expert Rev Respir Med.* 2024;18(12):975-989.
48. Amalakuhan B, Echevarria KL, Restrepo MI. Managing community acquired pneumonia in the elderly - the next generation of pharmacotherapy on the horizon. *Expert Opin Pharmacother.* 2017;18(11):1039-1048.
49. Arnold FW. How antibiotics should be prescribed to hospitalized elderly patients with community-acquired pneumonia. *Drugs Aging.* 2017;34(1):13-20.
50. Chen CW, Chen YH, Cheng IL, *et al.* Comparison of high-dose, short-course levofloxacin treatment vs conventional regimen against acute bacterial infection: meta-analysis of randomized controlled trials. *Infect Drug Resist.* 2019;12:1353-1361.

51. Furukawa Y, Luo Y, Funada S, *et al.* Optimal duration of antibiotic treatment for community-acquired pneumonia in adults: a systematic review and duration-effect meta-analysis. *BMJ Open*. 2023;13(3):e061023.
52. Lan SH, Lai CC, Chang SP, *et al.* Five-day antibiotic treatment for community-acquired bacterial pneumonia: A systematic review and meta-analysis of randomized controlled trials. *J Glob Antimicrob Resist*. 2020;23:94-99.
53. Tansarli GS, Mylonakis E. Systematic review and meta-analysis of the efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults. *Antimicrob Agents Chemother*. 2018;62(9):e00635-18.
54. Horwitz SL, Shen Y, Erdle SC, *et al.* Penicillin allergy de-labeling: Adaptation of risk stratification tool for patients and families. *World Allergy Organ J*. 2024;17(8):100939.
55. Chong CJ, Choo KJL, Ong KY, *et al.* Improving drug allergy label accuracy by supervised safety- and protocol-driven evaluation. *Ann Acad Med Singap*. 2022;51(11):677-85.
56. Dunbar LM, Wunderink RG, Habib MP, *et al.* High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. *Clin Infect Dis*. 2003;37(6):752-760.
57. Singh A. Fluoroquinolones should not be the first-line antibiotics to treat community-acquired pneumonia in areas of tuberculosis endemicity. *Clin Infect Dis*. 2007;45(1):133.
58. Li S, Li L, Wang S, *et al.* Clinical characteristics and risk factors of hospital mortality in elderly patients with community-acquired pneumonia. *Front Med (Lausanne)*. 2025;12:1512288.
59. Castro EM, Van Regenmortel T, Vanhaecht K, *et al.* Patient empowerment, patient participation and patient-centeredness in hospital care: A concept analysis based on a literature review. *Patient Educ and Couns*. 2016;99(12):1923-1939.
60. Kim S, Kim MJ, Myong JP, *et al.* Prior pneumococcal vaccination improves in-hospital mortality among elderly population hospitalized due to community-acquired pneumonia. *BMC Pulm Med*. 2024;24(1):168.